Angiotensin converting enzyme inhibition in cardiovascular risk populations: A practical approach to identify the patient who will benefit most

Current Opinion in Cardiology

Volumn 22, Issue 4, 2007, Pages 267-272

  Asselbergs, Folkert W ^a   Van Gilst, Wiek H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Albuminuria; Clinical trial; Kidney; LVH; Renin angiotensin system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANDOLAPRIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDICAL LITERATURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 34250167233     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3281a7ec81     Document Type: Review

References (50)

1. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet 2003; 362:755-757.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
3. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
4. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin- converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-2068.
5. Yusuf S, Sleight P, Pogue J, et al., The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
6. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
7. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588. Meta-analysis of the HOPE, EUROPA and PEACE trials.
8. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch Intern Med 2006; 166:787-796. Meta-analysis of the HOPE, QUIET, PART-2, SCAT, EUROPA, PEACE and CAMELOT trials.
9. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002; 18:1331-1339.
10. van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur Heart J 2005; 26:2361-2367.
11. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
12. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-convertingenzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
13. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality andmorbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
14. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002; 39:316-322.
15. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000; 36:S4-S9.
16. Raij L. Workshop: hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 2001; 37:767-773.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
18. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
19. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
20. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857-1863.
21. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
22. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
23. Candido R, Carraro M, Fior F, et al. Glomerular permeability defect in hypertension is dependent on renin angiotensin system activation. Am J Hypertens 2005; 18:844-850.
24. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
25. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
26. Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17:2582-2590. Data from the PREVEND program showing that macroalbuminuria and estimated GFR predict cardiovascular morbidity and mortality. Moreover, PREVEND demonstrated that macroalbuminuria is a better predictor of GFR loss than low eGFR in a population-based cohort.
27. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110:921-927.
28. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
29. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensinconverting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581.
30. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in microalbuminuric subjects. Circulation 2004; 110:2809-2816.
31. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45:281-287.
32. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
33. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93:1148-1154.
34. Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634-1638.
35. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90:2056-2069.
36. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104:1615-1621.
37. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
38. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343-2349.
39. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
40. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20:405-412.
41. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
42. Olsen MH, Wachtell K, Ibsen H, et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24:775-781. Substudy of LIFE demonstrating that baseline and in-treatment albuminuria level and LVH are independently related to cardiovascular events.
43. Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29:595-600. Substudy of LIFE demonstrating a relation between albuminuria lowering and a reduction in cardiovascular events in patients with hypertension, LVH and diabetes.
44. Pinto YM, de Smet BG, van Gilst WH, et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function andmorphology. Cardiovasc Res 1993;27:1933-1938.
45. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A 1982; 79:3310-3314.
46. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Prevention of the development of heart failure and the regression of cardiac hypertrophy by captopril in the spontaneously hypertensive rat. Eur Heart J 1983; 4 (Suppl A):143-148.
47. Tokmakova M, Solomon SD. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr Opin Cardiol 2006; 21:268-272. This article reviews the major clinical trials investigating the effects of RAS inhibition on cardiovascular events in patients with myocardial infarction and heart failure.
48. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16:149-160.
49. Jose P, Tomson C, Skali H, et al. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol 2006; 47:1725-1727. This substudy of the SAVE trial demonstrated the increased effectiveness of ACE inhibition in postmyocardial infarction patients with proteinuria at baseline.
50. Solomon SD, Rice MM, Jablonski A, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114:26-31. This substudy of the PEACE trial demonstrated the effectiveness of ACE inhibition in patients with reduced renal function and stable coronary artery disease.